All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
4 warning events since 2017; the latest 2026-09-18.
From the record
Filana Therapeutics, Inc.'s filings since 2017 show 4 warning events: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-09-18) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+18.9% a year over 5 filed years; profit years unseen.
From the record
Filana Therapeutics, Inc.'s 5 filed years say what it did: revenue went from $21 million in fiscal 2009 to $41 million in fiscal 2013, up 18.9% a year; it rose in 1 of 4 years; the deepest fall was 47% from fiscal 2009 to fiscal 2012 (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Filana Therapeutics, Inc.'s shareholder treatment is put at 7.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 28% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -122%: lost 122¢ per shareholder dollar. Leverage 37%: owes 37¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Filana Therapeutics, Inc. lost about 122 cents for every dollar of shareholders' money. Leverage: it owed about 37 cents per dollar of assets, and net share issuance: its share count grew 4.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 38% of 315 in its family.
From the record
Filana Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $41 million in fiscal 2013 ranks in the top 47% by size; revenue growth of 34.7% a year over the last 3 filed years ranks in the top 29% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 13% of 315 in its family for leadership; chief executive since 2024.
From the record
Filana Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Barry, Richard (President & CEO, as filed), filing under that title since 2024-10-01, 2.1 years (bottom 24% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 2.9 years (bottom 15%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 1%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 8.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Filana Therapeutics, Inc.'s room to expand is put at 8.2 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 18% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
top 45% of 306 in its family for growth drivers.
From the record
Filana Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2013: revenue grew 34.7% a year over the last three filed years against 18.9% over all 5, speeding up (top 16% of its family); the newest year grew 277.9% (top 10%); research spending grew -26.9% a year (bottom 15%); capital spending grew -40.2% a year (bottom 29%) (its annual reports). Filana Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 9.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Filana Therapeutics, Inc.'s expectations vs reality is put at 9.1 of 10 with a confidence of 35 of 100, because read from one part only, revenue against the prior three years' pace, which ranks in the top 9% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made